Pulses are racing!

Posted:
15
September 2004

Excitement is mounting at Richmond Pharmacology as we approach the QTc workshop to be held on 29th September 2004 at St George's Hospital Medical School. The workshop has received much interest and is expected to be a huge success.Richmond Pharmacology has invited main representatives from the top pharmaceutical companies to attend a workshop where world-leading experts in cardiology from St George's Hospital Medical School and also the Medicines and Healthcare Products Regulatory Authority (MHRA) will speak on a range of QTc topics.Studies focussing on the QT interval have become of increased importance recently. A number of drugs have been withdrawn from the market as a result of their capacity to cause potentially fatal arrhythmias associated with the prolongation of the QT interval. Factors influencing the QT interval, regulatory aspects of drug induced QT interval prolongation, correcting or controlling the QT interval, and the definitive QT study will all be discussed, among other topics, at the workshop hosted by Richmond Pharmacology.To find more information on Richmond Pharmacology's QTc capabilities, or for further information on the QTc workshop, follow the link to our QTc studies page.It is not too late to register, please see the workshop page for further information. The QTc Studies page provides up to date information on the services offered by RPL in this area of expertise.

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more